GC Biopharma Corp.
http://www.globalgreencross.com/eng/index.do
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From GC Biopharma Corp.
Lucky No. 13? Artiva Goes Public, Rises In First Day Of Trading
Artiva grossed $167m by selling more shares than previously planned, but at a significantly lower price per share than it proposed earlier in the week, to fund its NK cell therapy programs.
Finance Watch: US Market May Warm To Go-Public Options As Summer Progresses
Public Company Edition: The IPO market in the US cooled in Q2, but a warm-up may come in Q3 alongside new SPAC merger opportunities; Artiva may be the next biopharma firm to go public. Also, IDEAYA and Recursion grossed $302.4m and $200m, respectively, in follow-on offerings.
Q2 Korean Biotech Roundup: Partners Return Multiple Assets
The second quarter in South Korea was marked by the return of several assets by licensing partners, including Thea Open Innovation, which gave back rights to two ophthalmic programs in-licensed from OliX. Merck & Co. also cancelled a co-research deal with Artiva Biotherapeutics.
Korea Q1 Roundup: Pharma Begins To Feel Impact From Doctors’ Walkout
As South Korea's doctors continue their long-running protest against a government plan to raise the medical student quota at universities, the walk-outs may be beginning to take a toll on the pharma industry, with many large firms reporting weak earnings in the last quarter.
Company Information
- Industry
- Biotechnology
- Distributors
- Pharmaceuticals
- Contract Manufacturing Organization
- Other Names / Subsidiaries
-
- Ceragem Medisys
- Green Cross LabCell
- Green Cross Corporation
- GC Pharma
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice